X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Fabagal
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: ISU ABXIS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Fabagal
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: ISU ABXIS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2022
Details:
Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies.
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: CanSino Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
